HGEN - Humanigen rallies post HC Wainwright's Buy initiation
HC Wainwright initiated Humanigen ([[HGEN]] +16.6%) with a Buy rating, PT $31; indicating more than double upside from currently trading levels.Analyst Joseph Pantginis stated that the company's lead asset is lenzilumab and development is furthest along in treating COVID-19 patients.Clinical-Stage Pipeline: Lenzilumab in COVID-19:The underlying mechanism has generated promising data in patients, to date, and is now in the league with the major players, he further adds.Significant market potential for lenzilumab for COVID-19:
For further details see:
Humanigen rallies post HC Wainwright's Buy initiation